ClinicalTrials.gov
ClinicalTrials.gov Menu

High-dose IFN and PEG IFN for Induction Therapy in Difficult to Treat Genotype 1 Patients With Chronic HCV

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00381953
Recruitment Status : Completed
First Posted : September 28, 2006
Last Update Posted : March 13, 2015
Sponsor:
Information provided by:
Foundation for Liver Research

Brief Summary:
The purpose of this study is to compare pharmacokinetics by IFN assays and pharmacodynamics by patient's HCVRNA suppression of 360 mug peginterferon QW, 9 MU interferon daily or 4,5 MU interferon daily in combination with 180 mug peginterferon QW in the first 4 weeks of treatment. Comparison of virological breakthrough/relapse rate after dose adjustments and sustained virological response rate will be assessed by the type of induction.

Condition or disease Intervention/treatment Phase
Hepatitis C Drug: Peginterferon alfa-2a Drug: Interferon alfa-2a Drug: Ribavirin Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 33 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Comparative Study of High-dose Interferon Alfa-2a and Pegylated Interferon Alfa-2a for Induction Therapy in Difficult to Treat Genotype 1 Patients With Chronic HCV
Study Start Date : February 2003
Actual Primary Completion Date : April 2006
Actual Study Completion Date : July 2006

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: 360 PEG IFN
360 mug peginterferon alfa-2a QW
Drug: Peginterferon alfa-2a
Drug: Ribavirin
Active Comparator: 9 MU + 180 PEG IFN
9 MU interferon daily in combination with 180 mug peginterferon QW in the first 4 weeks of treatment
Drug: Peginterferon alfa-2a
Drug: Interferon alfa-2a
Drug: Ribavirin
Active Comparator: 4,5 MU IFN + 180 PEG IFN
4,5 MU interferon daily in combination with 180 mug peginterferon QW in the first 4 weeks of treatment
Drug: Peginterferon alfa-2a
Drug: Interferon alfa-2a
Drug: Ribavirin



Primary Outcome Measures :
  1. To compare pharmacokinetics by IFN assays and pharmacodynamics by patient's HCV RNA suppression of 360 mug peginterferon alfa-2a QW, 9 MU interferon alfa-2a daily or 4,5 interferon alfa-2a daily in combination with 180 mug peginterferon alfa-2a QW [ Time Frame: week 4 ]

Secondary Outcome Measures :
  1. To compare the virological breakthrough/relapse rate after dose adjustments (at 4,24,72) weeks. [ Time Frame: week 4, 24 and 72 ]
  2. To compare the sustained virological response rate at 24 weeks after end of treatment. [ Time Frame: week 24 follow up ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • chronic hepatitis C
  • detectable serum HCV-RNA
  • elevated serum ALT activity documented on at least two occasions within the past 12 months, with at least one during the 90 day screening period preceding the initiation of test drug dosing
  • liver biopsy findings (during screening or within previous 12 months) consistent with active fibrosis (haemophiliacs are excluded from biopsies)
  • compensated liver disease (Child-Pugh Grade A clinical classification)
  • negative urine or blood pregnancy test (for women of childbearing potential) documented within the 24-hour period prior to the first dose of study drug
  • all fertile males and females receiving ribavirin and their fertile or potentially fertile partners must be advised to use two forms of effective contraception (combined) during treatment and during the 6 months after end of treatment

Exclusion Criteria:

  • history or other evidence of severe illness, malignancy or any other condition which would make the patient, in the opinion of the investigator, unsuitable for the study
  • women with ongoing pregnancy or breast feeding
  • therapy with any systemic anti-viral, anti-neoplastic or immunomodulatory treatment (including supraphysiologic doses of steroids and radiation) <3 months prior to the first dose of study drug
  • any investigational drug <6 weeks prior to the first dose of study drug positive test at screening for HBsAg, anti-HIV Ab history or other evidence of bleeding from esophageal varices, ascites, or other conditions consistent with decompensated liver disease (Child-Pugh Grade B or C clinical classification)
  • Signs or symptoms of hepatocellular carcinoma
  • history or other strong evidence of a medical condition associated with chronic liver disease other than HCV (e.g., primary hemochromatosis, autoimmune hepatitis, metabolic liver disease, alcoholic liver disease, toxin exposures
  • Hb <7.5 mmol/l in women or <8.6 mmol/l in men at screening
  • any patient with an increased baseline risk for anaemia (e.g. thalassemia, spherocytosis, etc) or for whom anaemia would be medically problematic neutrophil count <1500 cells/mm3 or platelet count <80,000 cells/mm3 at screening
  • serum creatinine level >1.5 times the upper limit of normal at screening
  • history of severe psychiatric disease, especially depression
  • history of a severe seizure disorder or current anticonvulsant use
  • history of immunologically mediated disease
  • history or other evidence of chronic pulmonary disease associated with functional limitation
  • history of severe allergies
  • history of symptomatic and/or significant cardiovascular disease
  • poorly controlled diabetes mellitus
  • history of major organ transplantation with an existing functional graft
  • hyper- or hypothyroidism
  • evidence of severe retinopathy
  • evidence of drug abuse (including excessive alcohol consumption within one year before study entry

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00381953


Locations
Netherlands
Erasmus Medical Center
Rotterdam, Netherlands, 3015 CE
Sponsors and Collaborators
Foundation for Liver Research
Investigators
Principal Investigator: Rob J. de Knegt, MD, PhD Erasmus Medical Center

ClinicalTrials.gov Identifier: NCT00381953     History of Changes
Other Study ID Numbers: HCV02-01
First Posted: September 28, 2006    Key Record Dates
Last Update Posted: March 13, 2015
Last Verified: March 2015

Additional relevant MeSH terms:
Hepatitis C
Hepatitis, Viral, Human
Virus Diseases
Flaviviridae Infections
RNA Virus Infections
Hepatitis
Liver Diseases
Digestive System Diseases
Interferons
Ribavirin
Interferon-alpha
Peginterferon alfa-2a
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Immunologic Factors
Physiological Effects of Drugs